{
  "abstract": "Objective To determine the pharmaceutical interventions in patients eligible for phase I cancer clinical trials, focusing specifically on exclusion criteria related to medication or relevant interactions.Method Descriptive, observational study conducted at a comprehensive cancer centre. Patients undergoing screening for phase I clinical trials (March 2019–December 2022) were included. The pharmacist reviewed concomitant medication and provided a recommendation.Results The concomitant medication of 512 patients eligible to participate in 84 phase I clinical trials was analysed. In 230 (44.9%) patients, the clinical trial treatment included oral medication. The median number of concomitant medications was 5 (IQR 3–8) per patient.A total of 280 pharmaceutical interventions were performed in 140 (27.3%) patients: 240 (85.7%) were due to interactions in 124 (24.2%) patients, and 40 (14.3%) were due to exclusion criteria in 34 (6.6%) patients. Interactions and exclusion criteria were detected in 18 (3.5%) patients. The main groups of drugs involved were 68 (24.3%) antacids and antiulcer drugs, 28 (10.0%) antidepressants and 26 (9.3%) opioids. Acceptance analysis of the recommendation was applicable in 215 cases; in 208 (96.7%), the pharmaceutical intervention was accepted.Differences were identified for exclusion criteria (7 vs 27) and interactions (37 vs 87) between parenteral and oral clinical trial medication (p<0.001).Conclusion The pharmacist’s review of concomitant medication during the screening period in phase I clinical trials enables the detection of prohibited medication or relevant interactions, potentially avoiding screening failures and increasing the efficacy and safety of treatments.",
  "authors": [
    {
      "affiliations": [
        "Pharmacy Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain"
      ],
      "name": "Rosa Rodríguez-Mauriz"
    },
    {
      "affiliations": [
        "Pharmacy Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain"
      ],
      "name": "Monica González-Laguna"
    },
    {
      "affiliations": [
        "Pharmacy Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain"
      ],
      "name": "Maria Perayre-Badia"
    },
    {
      "affiliations": [
        "Pharmacy Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain"
      ],
      "name": "Toni Lozano-Andreu"
    },
    {
      "affiliations": [
        "Pharmacy Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain"
      ],
      "name": "Maria Emilia Miquel-Zurita"
    },
    {
      "affiliations": [
        "Pharmacy Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain"
      ],
      "name": "Salomé Cañizares-Paz"
    },
    {
      "affiliations": [
        "Pharmacy Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain"
      ],
      "name": "Lorena Santulario-Verdú"
    },
    {
      "affiliations": [
        "Pharmacy Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain"
      ],
      "name": "Marina Millan-Coll"
    },
    {
      "affiliations": [
        "Pharmacy Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain",
        "Instituto de Investigación Biomédica de Bellvitge, Barcelona, Spain"
      ],
      "name": "Sandra Fontanals"
    },
    {
      "affiliations": [
        "Pharmacy Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain",
        "Instituto de Investigación Biomédica de Bellvitge, Barcelona, Spain"
      ],
      "name": "Ana Clopés-Estela"
    }
  ],
  "title": "Pharmaceutical care in the screening process of phase I oncohaematological clinical trials",
  "uid": "e19b398c-a469-598f-aabf-53b4bd5bad62"
}